About Technology COVID-19 Media Contact Us Careers Our end-to-end technology will create a safe, reliable, and affordable supply of medicines on demand. 1 COVID-19 Pandemic Reveals Weaknesses The COVID-19 pandemic has served as a wake-up call—revealing weaknesses in global and U.S. medicine manufacturing and distribution. 90% of active ingredients and 60% of finished dosage forms are made at facilities outside the U.S. 72% of the API manufacturers supplying the U.S. market are overseas and the vast majority are located in China and India. 70% of India’s imports of APIs come from China. In March 2020, during a spike in U.S. COVID-19 cases, India restricted the export of 26 APIs and medicines, including antivirals and pain relievers. The pandemic has exposed a new type of challenge–an inability to deliver products to all areas of the U.S. equitably. According to testimony presented by RAND, the quantities of material in the stockpile were not nearly enough to fill all the requests, resulting in a heated supply competition, and an inability to deliver products across the United States equitably. VISION FOR THE FUTURE: POINT-OF-CARE POD Opportunities To Advance Pharmaceutical Manufacturing The weaknesses revealed by the COVID-19 pandemic also present opportunities to advance pharmaceutical manufacturing into the 21st century. The security of the nation’s drug supply rests on three main factors: freedom from dependence on foreign sources of API, the resilience of our domestic manufacturing base, and the reliability of the facilities that make products for the U.S. market. Dr. Janet Woodcock, Director of the Center for Drug Evaluation and Research (CDER) at the FDA in testimony given before the House Committee on Energy and Commerce, Oct. 19, 2019 To achieve the goal of medicine self-sufficiency, it is essential that the U.S. establish a critical manufacturing infrastructure that is end-to-end, automated and has the flexibility to be distributed. U.S. Pharmaceutical Manufacturing Needs ODP Capabilities End-to-end manufacturing Automated manufacturing Advanced Quality Management Systems Ability to respond quickly to surges and crises Resilient distributed manufacturing model A distributed network of PoDsTM will: IMPROVE U.S. GLOBAL COMPETITIVENESS ESTABLISH THOUSANDS OF NEW HIGH-PAYING U.S. JOBS REDUCE WASTE THROUGH NEW, GREEN TECHNOLOGY CREATE HIGH-QUALITY, AFFORDABLE DRUGS TO SUPPORT HEALTH AND WELL-BEING © 2021 On Demand Pharmaceuticals Inc. | Privacy Policy